The antiepileptic drug sodium va/proate (NaVP) is a widely used mood stabilizer and seizure controlling drug. Prospective and retrospective studies have suggested that the use of sodium valproate as an antiepileptic drug during pregnancy may be related to the increased incidence of the malformations of the cardiovascular and urogenital systems (Nau et aI.,
1981a; Robert and Guibaud, 1982; Kock et aI., 1983; Mastroiacovo et aI., 1983 and Winter et al., 1987). A fetal valproate syndrome (FVS) consisting of minor congenital anomalies has been described by Diliberti et al. (1984). In this syndrome, the dysmorphic features include epicanthal folds, strabismus, flat nasal bridge, upturned nasal tip, shallow philtrum, downturned mouth, microcephaly, radial aplasia and hyperconvex nails. Retarded psychomotor development has also been reported (Jager et aI., 1987).